Almost six years after Novartis AG sold off its vaccine division to rival GSK, the Swiss drug major is assessing its way back into the vaccine space, however differently this time.
CNBC-TV18’s Archana Shukla caught up with Lutz Hegemann, Group Head-Corporate Affairs of the pharma company at BioAsia 2021, and asked if there is any re-entry at the vaccine front.
“To an extent yes, but not that we would reactivate our former vaccine division because we would subscale and not competitive if we do not have all the resources at our end. Therefore, we are not looking to launch competitive COVID vaccine programmes," he said.
“When you have 5-10-20 vaccine candidates, I think it is more important that you focus on a few and help to accelerate those who want to increase manufacturing capacity. I believe it's more of a service to mankind than trying to have competing research programmes that potentially maybe subscale or may not get you to the desired outcome,” he said.
For more details, watch the video.